There’s no need to dive fast and furious into every single wellness trend, according to a Ludacris-fronted campaign from Bayer’s consumer health division.

Addressing pressing questions about upcoming ATTR-CM competition and market opportunity, Alnylam management on Tuesday outlined a path for Amvuttra to become the revenue leader in an expansive ATTR-CM space of more than 75,000 U.S.-treated patients by 2030.

The new company, looking to eliminate costly manufacturing bottlenecks by producing biologic medicines in chicken eggs, has now lined up a commercial taker.

After becoming a prominent public face of the CDC’s revamped Advisory Committee on Immunization Practices, Robert Malone, M.D., has reportedly stepped down from his role, citing mounting drama in recent weeks.

Roche’s Genentech is backing this year’s Walk to End Lupus Now, taking up a sponsorship opportunity claimed by GSK in previous years.

The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three prior lines of systemic treatment, at least one of which had to include bevacizumab.